Abstract
What is the efficacy of calcitonin gene-related peptide (CGRP) inhibitors in migraine prophylaxis? Treating 5 to 8 patients with CGRP inhibitors will lead to 1 patient having at least a 50% reduction in monthly migraine days (MMD) compared with placebo. From baseline, a decrease of 1 to 2 MMD may
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Canadian family physician Medecin de famille canadien
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
